About Us

Opulink Corporation  supports the pharmaceutical and health care industries at the most fundamental level.  We take a “fresh” approach to helping solve the site and patient recruitment problems because of our extensive work experience as professional recruiters and experience in recruitment advertising.

Our “value add” to the industry is to cut the time involved in both site and patient recruitment, therefore saving both money and time in completing clinical trials.

Recently, a senior VP at a large CRO told us that “the direction of the CROs and Sponsors over the next 10 years is to focus on obtaining quality sites (investigators) and seeking out the vendors who can provide effective, timely site and patient recruitment”.

Our key team members and management have many successful years in the recruiting, clinical trials, advertising, and database areas which position us perfectly in providing the needed solutions to the clinical trials sponsors - the major pharmaceuticals.

Our goal is to “automate” the site recruitment, patient recruitment, and research databases so that we can scale the processes more easily. Responding to the need for the start-up phase of clinical trials to be shorter, we have already proven that we can cut the time from months to weeks, as we have on our current trials!

Opulink is part of the next generation of service providers consisting of trial management organizations (TMO) and site management organizations (SMO) which have expanded their services to help pharmaceutical companies and CROs (Contract Service Organizations) accelerate study startup time by identifying qualified investigative sites suitable for their clinical studies!

We add value for both the sponsor (cost savings and time) and the investigator (bringing clinical trials to their practices) by:

• SITE SUPPORT (investigators)- business development support (bringing study opportunities to the sites), patient recruitment and retention, budget and contract negotiation, tracking metrics on site performance,  training, regulatory support, site management for Phase 1-4 studies, facilitate direct sponsor and CRO interaction with the site.

• SPONSOR/CRO SUPPORT (pharmaceuticals))- speed up the startup phase of clinical research with pre-qualified investigators, conduct feasibility studies based on a protocol to determine potential site and patient populations, patient recruitment and retention, and site management for  Phase 1-4 studies.

Opulink has developed new partnerships and tools to accelerate our value to the industry:  1) partnership with GOC,  2) CureBridge patient database, and
3) Phenotypic/Genotypic Clinical trials:

Our Unique Partnership with the Geriatric Oncology Consortium (GOC)
Opulink and the GOC have formed a partnership in order to expand the capabilities of each in patient and site recruitment and the ability to conduct Phase I through IV Oncology clinical trials. The GOC has 1,100 research sites nationally and Opulink will provide site management services to those sites.

CureBridgeSM Database.
We have developed a proprietary web-based user interface system that registers potential clinical trial participants, investigators and new drug sponsors.  The system supports information search functions based on common information points such as nature of infirmity, zip code, geographic co-ordinates, patient interest, investigator name, sponsor name and therapeutic specialty.  We will market to clinical trial administrators (new drug sponsors and clinical research organizations) the service of matching participants to clinical trials, feasibility studies for future trials, and surveys garnering specific information on  select groups of  people who are similarly situated (i.e., suffering from the same disease, the same age, the same geographic area, etc.)  We know from industry discussions that the functionality of our database will be exceptionally valuable to the pharmaceutical, biotechnical and healthcare industries.

Phenotypic and Genotypic Clinical Trials
The medical research community has begun to realize that the effective treatment of a variety of chronic diseases would be greatly served through the gathering of basic (phenotypic) and genetic (genotypic) data from patients.  These specialized clinical trials will build defined databases for future research projects, earning Opulink repeated grants for the research.